215 related articles for article (PubMed ID: 25936599)
1. A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients.
Oberije C; De Ruysscher D; Houben R; van de Heuvel M; Uyterlinde W; Deasy JO; Belderbos J; Dingemans AM; Rimner A; Din S; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):935-44. PubMed ID: 25936599
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
Lee DH; Han JY; Cho KH; Pyo HR; Kim HY; Yoon SJ; Lee JS
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1037-44. PubMed ID: 16024178
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.
Dingemans AM; Bootsma G; van Baardwijk A; Reymen B; Wanders R; Brans B; Das M; Hochstenbag M; van Belle A; Houben R; Lambin P; de Ruysscher D
J Thorac Oncol; 2014 May; 9(5):710-6. PubMed ID: 24722157
[TBL] [Abstract][Full Text] [Related]
5. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy.
Dehing-Oberije C; Yu S; De Ruysscher D; Meersschout S; Van Beek K; Lievens Y; Van Meerbeeck J; De Neve W; Rao B; van der Weide H; Lambin P
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):355-62. PubMed ID: 19095367
[TBL] [Abstract][Full Text] [Related]
6. Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries.
Jochems A; Deist TM; El Naqa I; Kessler M; Mayo C; Reeves J; Jolly S; Matuszak M; Ten Haken R; van Soest J; Oberije C; Faivre-Finn C; Price G; de Ruysscher D; Lambin P; Dekker A
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):344-352. PubMed ID: 28871984
[TBL] [Abstract][Full Text] [Related]
7. Effect analysis of chemoradiotherapy after operation in patients with stage III A non-small cell lung cancer.
Chen S; Cheng YL; Li ST; Ni YJ; Gu B
Asian Pac J Trop Med; 2012 Oct; 5(10):823-7. PubMed ID: 23043924
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Kim YH; Ahn SJ; Kim YC; Kim KS; Oh IJ; Ban HJ; Chung WK; Nam TK; Yoon MS; Jeong JU; Song JY
Jpn J Clin Oncol; 2016 Feb; 46(2):144-51. PubMed ID: 26590014
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Luo J; Leaw SJ; Xu Y; Zheng D
Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
[TBL] [Abstract][Full Text] [Related]
12. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
13. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
15. Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study.
Gagel B; Piroth M; Pinkawa M; Reinartz P; Krohn T; Kaiser HJ; Stanzel S; Breuer C; Asadpour B; Schmachtenberg A; Eble MJ
BMC Cancer; 2007 Jun; 7():112. PubMed ID: 17598906
[TBL] [Abstract][Full Text] [Related]
16. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
De Petris L; Lax I; Sirzén F; Friesland S
Med Oncol; 2005; 22(4):375-81. PubMed ID: 16260855
[TBL] [Abstract][Full Text] [Related]
17. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
Gridelli C; Gallo C; Shepherd FA; Illiano A; Piantedosi F; Robbiati SF; Manzione L; Barbera S; Frontini L; Veltri E; Findlay B; Cigolari S; Myers R; Ianniello GP; Gebbia V; Gasparini G; Fava S; Hirsh V; Bezjak A; Seymour L; Perrone F
J Clin Oncol; 2003 Aug; 21(16):3025-34. PubMed ID: 12837810
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic strategies in advanced non-small cell bronchial cancers: platin-based combinations].
Fournel P
Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S42-7. PubMed ID: 12538935
[No Abstract] [Full Text] [Related]
[Next] [New Search]
